Policy | February 02, 2024
Industry’s reaction to Union Budget 2024-25
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Indian Pharma Post brings together the views of industry leaders on the Interim Union Budget 2024-25 announcement and its impact on the industry
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
Comprehensive clinical development programs being initiated for each investigational candidate
Sirius JV will be owned 51% by Sirius and 49% by Adani
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
The initiation of the second clinical trial in the INTerpath program represents rapid expansion in research for additional tumor types for individualized neoantigen therapy, V940 (mRNA-4157)
High-quality baobab oil sourced in collaboration with UNCCD and the Great Green Wall Initiative
Equipped with most advanced Distributed Control System (DCS) automation technology, the facility has been set up with an investment of Rs. 200 crore
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Subscribe To Our Newsletter & Stay Updated
